Results 321 to 330 of about 399,504 (355)

Safety of upadacitinib in atopic dermatitis in randomized clinical trials across 6 years

Journal of the European Academy of Dermatology and Venereology, EarlyView.
The current study found no evidence of cumulative increased safety risks with upadacitinib 15 or 30 mg for up to 6 years and over 9000 patient‐years of safety data in adults and adolescents. There were low rates of adjudicated major adverse cardiovascular events, adjudicated thromboembolic events and malignancies. Abstract Background Atopic dermatitis (
Christopher G. Bunick, Alan D. Irvine, Jonathan I. Silverberg, Emma Guttman‐Yassky, Mona Shahriari, Xinghua Gao, Stephan Weidinger, Norito Katoh, Namita Vigna, Deanne M. Dilley, Elvira D'Andrea, Henrique D. Teixeira, Andrew M. Platt, Gweneth F. Levy   +13 more
wiley   +1 more source

Evidence of jak2 val617phe positive essential thrombocythemia with splanchnic thrombosis during estroprogestinic treatment [PDF]

, 2008
Colagrande, M, Di Ianni,M, Lapecorella, M, Lucchesi,A, Mariani, G., NAPOLITANO, Mariasanta, Tabilio, A   +6 more
core  

Predictive Factors of Response and Real‐World Experience of Baricitinib on Alopecia Areata: A Single Tertiary Center Study on a 72 Patients' Cohort

International Journal of Dermatology, EarlyView.
Alonso García‐Núñez, Antonio Alcalá Ramírez Del Puerto, Roberto Daza‐García, María Teresa Monserrat‐García, Mercedes Morillo‐Andújar, Javier Jesús Domínguez‐Cruz, Román Barabash‐Neila   +6 more
wiley   +1 more source

Elastolytic Granulomatous Dermatoses: Toward a Unified Clinicopathological Concept

International Journal of Dermatology, EarlyView.
Rose Kathrin Caroline Moritz, Christiane Michl, Sonja Leson   +2 more
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

N-(Pyrimidin-2-yl)-1,2,3,4-tetrahydroisoquinolin-6-amine Derivatives as Selective Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.

Journal of Medicinal Chemistry, 2020
In this study, we described a series of N-(pyrimidin-2-yl)-1,2,3,4-tetrahydroisoquinolin-6-amine derivatives as selective JAK2 (Janus kinase 2) inhibitors.
Tao Yang, Mengshi Hu, Yong Chen, Mingli Xiang, Ming-hai Tang, Wenyan Qi, Mingsong Shi, Jun He, X. Yuan, Chufeng Zhang, Kongjun Liu, Jiewen Li, Zhuang Yang, Lijuan Chen   +13 more
semanticscholar   +1 more source

Discovery of a Potent and Selective Tyrosine Kinase 2 Inhibitor: TAK-279.

Journal of Medicinal Chemistry, 2023
TYK2 is a key mediator of IL12, IL23, and type I interferon signaling, and these cytokines have been implicated in the pathogenesis of multiple inflammatory and autoimmune diseases such as psoriasis, rheumatoid arthritis, lupus, and inflammatory bowel ...
S. Leit, Jeremy Greenwood, S. Carriero, Sayan Mondal, R. Abel, M. Ashwell, Heather S. Blanchette, Nicholas A Boyles, M. Cartwright, A. Collis, Shulu Feng, Phani Ghanakota, G. Harriman, V. Hosagrahara, N. Kaila, Rosanna Kapeller, Salma Rafi, D. Romero, P. Tarantino, Jignesh B. Timaniya, A. Toms, Ron Wester, W. Westlin, Bhaskar Srivastava, Wenyan Miao, P. Tummino, J. McElwee, S. Edmondson, Craig Masse   +28 more
semanticscholar   +1 more source

Janus kinase 2 inhibitors in myeloproliferative disorders

Expert Opinion on Investigational Drugs, 2010
JAK2 is an obligatory kinase for the proliferation and differentiation of erythroid cells and megakaryocytes thus representing a relevant therapeutic target for agents that specifically inhibit its activity particularly in myeloproliferative disorders (MPD) harboring JAK2(V617F) mutations.We discuss the physiopathology of the JAK2 signaling pathway and
Lucia E, Recchia AG, Gentile M, Bossio S, Vigna E, Mazzone C, Madeo A, Morabito L, Gigliotti V, De Stefano L, Caruso N, Servillo P, Franzese S, Bisconte MG, Gentile C, Morabito F.   +15 more
openaire   +3 more sources

Downregulation of KCNQ4 by Janus Kinase 2

The Journal of Membrane Biology, 2013
Janus kinase-2 (JAK2) participates in the signaling of several hormones, growth factors and cytokines. Further stimulators of JAK2 include osmotic cell shrinkage, and the kinase activates the cell volume regulatory Na(+)/H(+) exchanger. The kinase may thus participate in cell volume regulation. Cell shrinkage is known to inhibit K(+) channels.
Hosseinzadeh, Zohreh, Sopjani, Mentor, Pakladok, Tatsiana, Bhavsar, Shefalee K., Lang, Florian   +4 more
openaire   +3 more sources

Janus kinase inhibitors for atopic dermatitis: a promising treatment modality

Clincal and Experimental Dermatology, 2021
Atopic dermatitis (AD) is chronic, pruritic, inflammatory skin disease that affects a significant portion of the population in industrialized nations. For nonresponders to conventional therapies, AD can significantly reduce sleep quality and quality of ...
A. Cartron, T. H. Nguyen, Y. Roh, M. Kwatra, S. Kwatra   +4 more
semanticscholar   +1 more source

Prolactin Promotes Hepatocellular Carcinoma through Janus Kinase 2

World Journal of Surgery, 2012
AbstractBackgroundHepatocelluar carcinoma (HCC) is one human cancer with obvious gender disparity. This study investigated the association of aberrant prolactin levels with HCC risk and the potential impacts on HCC of the prolactin receptor (PRLR)/Janus kinase 2 (JAK2) signaling.MethodsSerum prolactin of 63 HCC patients and 162 subjects without HCC was
Yao-Tsung, Yeh, King-Teh, Lee, Chia-Jung, Tsai, Yu-Jie, Chen, Shen-Nien, Wang   +4 more
openaire   +2 more sources